Skip to main content
SpringerLink
Log in

Endophthalmitis After Intravitreal Injections

  • Chapter
  • First Online:
Endophthalmitis

  • 596 Accesses

Abstract

Endophthalmitis after intravitreal injections is a rare but devastating complication of this common eye procedure. Patients typically present within 5 days of their injection with decreased vision, pain, and redness. However, the absence of any one of these in the presence of other symptoms should not exclude the diagnosis of endophthalmitis. Treatment consists of obtaining a vitreous sample and administering intravitreal antibiotics. Vitrectomy may be indicated in some cases. Preventive measures include the use of a lid speculum and topical povidone-iodine during the procedure, and clinicians may consider the use of masks or having all participants refrain from speaking.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ramulu PY, Do DV, Corcoran KJ, Corcoran SL, Robin AL. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128(10):1335–40. doi:10.1001/archophthalmol.2010.224.

    Article  PubMed  Google Scholar 

  2. Kim JY, Wang SJ, Park CJ, Lee SB. Risk factors leading to enucleation or evisceration in endophthalmitis. J Korean Ophthalmol Soc. 2007;48(10):1362. doi:10.3341/jkos.2007.48.10.1362.

    Article  Google Scholar 

  3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–98. doi:10.1016/j.ophtha.2012.03.053.

    Google Scholar 

  4. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. doi:10.1016/j.ophtha.2013.02.034.

    Article  PubMed  Google Scholar 

  5. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124–33.e1. doi:10.1016/j.ophtha.2010.02.022.

    Google Scholar 

  6. Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Ophthalmology. 2011;118(12):2453–60. doi:10.1016/j.ophtha.2011.05.014.

    Article  PubMed  Google Scholar 

  7. Mccannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Retina. 2011;31:654–61. doi:10.1097/iae.0b013e31820a67e4.

    Article  CAS  PubMed  Google Scholar 

  8. Fileta JB, Scott IU, Flynn HW. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014;45(2):143–9. doi:10.3928/23258160-20140306-08.

    Article  PubMed  Google Scholar 

  9. VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;0(0). doi:10.1016/j.ophtha.2015.07.005.

    Google Scholar 

  10. Yoon SJ, Rhee DY, Marx JL, et al. Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone. Am J Ophthalmol. 2009;147:1031–6.

    Article  CAS  PubMed  Google Scholar 

  11. Ahn SJ, Kim TW, Ahn J, et al. Associated factors and treatment outcome of presumed noninfectious endophthalmitis occurring after intravitreal triamcinolone acetonide injection. Graefes Arch Clin Exp Ophthalmol. 2013;251:715–23.

    Article  CAS  PubMed  Google Scholar 

  12. Fine H, Despotidis GD, Prenner JL. Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol. 2015;26:184–7.

    Article  PubMed  Google Scholar 

  13. Lyall DAM, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26(12):1517–26. doi:10.1038/eye.2012.199.

    Article  CAS  Google Scholar 

  14. Moshfeghi AA, Rosenfeld PJ, Flynn HW, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists. Retina. 2011;31(4):662–8. doi:10.1097/iae.0b013e31821067c4.

    Article  CAS  PubMed  Google Scholar 

  15. Garg SJ, Dollin M, Hsu J, et al. Effect of a strict “no-talking” policy during intravitreal injection on post-injection endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2015;46:1028–34.

    Article  PubMed  Google Scholar 

  16. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008;92(12):1606–11. doi:10.1136/bjo.2007.132597.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chen RWS, Rachitskaya A, Scott IU, Flynn HW. Is the use of topical antibiotics for intravitreal injections the standard of care or are we better off without antibiotics? JAMA Ophthalmol. 2013;131(7):840. doi:10.1001/jamaophthalmol.2013.2524.

    Article  PubMed  Google Scholar 

  18. Storey P, Dollin M, Pitcher J, et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283–9. doi:10.1016/j.ophtha.2013.08.037.

    Article  PubMed  Google Scholar 

  19. Cheung CSY, Wong AWT, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–14. doi:10.1016/j.ophtha.2012.02.014.

    Article  PubMed  Google Scholar 

  20. Ahmed Y, Scott IU, Pathengay A, Bawdekar A, Flynn HW. Povidone-iodine for endophthalmitis prophylaxis. Am J Ophthalmol. 2014;157(3):503–4. doi:10.1016/j.ajo.2013.12.001.

    Article  CAS  PubMed  Google Scholar 

  21. Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophthalmol. 2014;157(3):514–8.e1. doi: 10.1016/j.ajo.2013.10.003.

    Google Scholar 

  22. Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance: a randomized, controlled study of patients undergoing intravitreal injections. Ophthalmology. 2011;118:1358–63.

    PubMed  Google Scholar 

  23. Haddock LJ, Ramsey DJ, Young LH. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications. Semin Ophthalmol. 2014;29(5–6):257–62. doi:10.3109/08820538.2014.959616.

    Article  PubMed  Google Scholar 

  24. Friedman DA, Mason JO, Emond T, Mcgwin G. Povidone–iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975–81. doi:10.1097/iae.0b013e3182877585.

    Article  CAS  PubMed  Google Scholar 

  25. Wen JC. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551. doi:10.1001/archophthalmol.2011.227.

    Article  PubMed  Google Scholar 

  26. Schimel AM. Endophthalmitis after intravitreal injections. Arch Ophthalmol. 2011;129(12):1607. doi:10.1001/archophthalmol.2011.370.

    Article  PubMed  Google Scholar 

  27. Wykoff CC, Flynn HW. Endophthalmitis after intravitreal injection: prevention and management. Retina. 2011;31(4):633–5. doi:10.1097/iae.0b013e31821504f2.

    Article  PubMed  Google Scholar 

  28. Chaudhary KM, Romero JM, Ezon I, Fastenberg DM, Deramo VA. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection. Retina. 2013;33(7):1407–16. doi:10.1097/iae.0b013e3182807659.

    Article  CAS  PubMed  Google Scholar 

  29. Goldberg RA, Flynn HW, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–8.e1. doi: 10.1016/j.ajo.2011.11.035.

    Google Scholar 

  30. Goldberg RA, Flynn HW, Miller D, Gonzalez S, Isom RF. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology. 2013;120(7):1448–53. doi:10.1016/j.ophtha.2012.12.009.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn’t blind people, people blind people. Am J Ophthalmol. 2012;153(2):196–203.e1. doi:10.1016/j.ajo.2011.11.023.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    John B. Miller MD & Joan W. Miller MD

  2. Department of Ophthalmology, Massachusetts Eye and Ear and Massachusetts General Hospital, Boston, MA, USA

    John B. Miller MD & Joan W. Miller MD

  3. Department of Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, FL, USA

    Luis J. Haddock MD

Authors
  1. John B. Miller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis J. Haddock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joan W. Miller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John B. Miller MD .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Marlene L. Durand

  2. Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA

    Joan W. Miller

  3. Massachusetts Eye and Ear, Harvard Medical School, BOSTON, Massachusetts, USA

    Lucy H. Young

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Miller, J.B., Haddock, L.J., Miller, J.W. (2016). Endophthalmitis After Intravitreal Injections. In: Durand, M., Miller, J., Young, L. (eds) Endophthalmitis. Springer, Cham. https://doi.org/10.1007/978-3-319-29231-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-29231-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-29229-8

  • Online ISBN: 978-3-319-29231-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation